Content Type: Article

  • Brazil’s LGPD Takes Effect – With Early Enforcement

    Brazil’s LGPD Takes Effect – With Early Enforcement

    ARTICLE / CLIENT ALERT

    Brazil’s LGPD Takes Effect – With Early Enforcement

    September 28, 2020

    Read time: 7 min

    Key takeaways
    Overview

    Brazil represents over half of all IT spend in Latin America, has the largest regional market for software outsourcing, employs a sizable IT workforce, manufactures consumer goods (including commercial airplanes and cars) and has an active consumer market of social media operated by global data aggregators. At a time when data privacy is becoming increasingly important to consumers, it seems only fitting that Brazil would adopt comprehensive privacy legislation to protect data privacy rights.

    The General Data Protection Law, the first law of its kind in Brazil, is now in effect, and we are already seeing enforcement. Streamlining the legal framework on data protection, the law sets forth a number of requirements addressing legal bases for processing, individual rights, governance and accountability and data transfers. Here’s what you need to know.

    In depth

    What is LGPD?

    The General Data Protection Law (LGPD) is Brazil’s first comprehensive data protection law and is designed to enhance the privacy and protection of personal data of individuals in Brazil. The LGPD heavily resembles the EU General Data Protection Regulation (GDPR).

    When did the LGPD take effect?
    After a long period of uncertainty regarding LGPD’s implementation, the Federal Senate of Brazil issued an amendment which accelerated the LGPD’s effective date, setting an immediate effective date upon enactment of the amendment on August 27, 2020. On September 17, 2020, the Brazilian president approved the bill, resulting in the LGPD taking effect on September 18, 2020.

    While the LGPD’s implementing regulations have yet to be released, and administrative enforcement has been delayed until August 2021, the Constitution of the Federative Republic of Brazil grants a private right of action to all citizens and a public right of action to Brazil’s “Ministério Público” or “MP” (Brazil Public Prosecutors’ Office). Private lawsuits and public prosecutor actions based on the LGPD’s main provisions may be possible now that the law has taken effect. Please review our summary of enforcement below for an overview of the potential penalties for violating the LGPD and the recent public civil action filed just three days after the LGPD took effect.

    To whom does the LGPD apply?
    Similar to the General Data Protection Regulation (GDPR) in the European Union and European Economic Area, the LGPD has extraterritorial reach. The law generally applies to any organization that processes personal data of individuals in Brazil regardless of where the organization is located, and irrespective of where the data is stored or otherwise processed, if: (i) the processing is carried out or collected in Brazil; (ii) the purpose of the processing is to offer or provide goods or services to individuals in Brazil; or (iii) the purpose of the processing is to process personal data of individuals in Brazil.

    What did the LGPD change?
    Before the LGPD, Brazil’s data protection legal framework was a patchwork of laws, consisting of a federal constitutional right to privacy and several different sectoral laws and regulations. The LGPD streamlines the legal framework by replacing certain regulations and supplementing others, and sets forth a number of requirements addressing legal bases for processing, individual rights, governance and accountability and data transfers. The most significant requirements of the LGPD include the following:

    Legal Bases for Processing
    Under the LGPD, organizations must have a legal base to process personal data. They may do so:

    • With the data subject’s consent;
    • To comply with a legal or regulatory obligation;
    • By the public administration, for the processing and shared use of data when necessary for the execution of public policies;
    • To carry out studies by research entities;
    • Where necessary for the execution of a contract with the data subject;
    • For the regular exercise of rights in judicial, administrative or arbitration procedures;
    • For the protection of life or physical safety of the data subject or a third party;
    • To protect health, in a procedure carried out by a health professional or health entity;
    • When necessary to fulfill the legitimate interests of the organization or a third party, except when the data subject’s fundamental rights and liberties outweigh the organization’s interest; or
    • To protect an individual’s credit.

    Individual Rights
    Data subjects in Brazil have a number of rights over their personal data, including the rights to:

    • Confirm the existence of processing, including whether the organization holds particular data
    • Access the data subject’s personal data
    • Access information about entities with whom the organization has shared the data subject’s personal data
    • Correct incomplete, inaccurate or out-of-date personal data
    • Anonymize, block or delete unnecessary or excessive personal data or personal data processed out of compliance with the LGPD
    • Port or transfer their personal data to another service or product provider
    • Delete personal data processed on the basis of consent
    • Request information about the possibility of denying consent and the consequences of such denial and the right to revoke consent.

    Governance & Accountability
    Generally speaking, organizations subject to the LGPD must take the following steps to meet their compliance obligations:

    • Appoint a data protection officer (controllers only)
    • Maintain records of processing activities
    • Implement and maintain privacy notices
    • Report security incidents to the National Data Protection Authority (ANPD) and to data subjects within a “reasonable” time period, if the security incident may create risk or relevant damage to the data subjects
    • Perform data protection impact assessments
    • Develop products and services using the principle of privacy-by-design
    • Adopt security, technical and administrative measures to safeguard personal data from authorized access and accidental or unlawful destruction, loss, alteration, communication or any type of improper or unlawful processing.

    Data Transfers
    Organizations subject to LGPD may export data internationally if:

    • The data protection authority issues an adequacy finding for the recipient jurisdiction; or
    • The controller is able to guarantee compliance with the principles and rights of the data subject, in the form of:
      • Specific contractual clauses for a given transfer;
      • Standard contractual clauses;
      • Binding corporate rules;
      • Regularly issued stamps, certificates or codes of conduct; or
    • The organization has obtained the data subject’s specific and express consent, distinct for the transfer.

    Enforcement
    Violations of the LGPD may result in fines of up to 2% of the organization’s Brazilian revenue for the prior year, up to a total of 50 million reais (or approximately $9.3 million USD) per violation.

    Merely three days after the LGPD took effect, the Ministério Público do Distrito Federal e dos Territórios’ (MPDFT) Special Data Protection and Artificial Intelligence Unit filed the first public civil action alleging that violations of the LGPD violate the right to privacy, privacy and image, which are guaranteed by the Constitution of the Federative Republic of Brazil. The MPDFT filed the lawsuit against a data services company that allegedly sold the personal data of 500,000 Brazilian individuals. The complaint also stated that potential buyers of data can purchase categories of personal data, such as data from hairdressers, brokers, dentists, doctors, nurses, psychologists and other professionals from specific states in Brazil. The MPDFT is seeking an urgent preliminary injunction to prohibit the company from disclosing (for sale or otherwise) personal data and to have the company’s website domain be frozen until the courts reach a final decision. This action may encourage other MPs to begin enforcing violations to protect individuals’ data privacy rights.

    Next Steps
    The LGPD still has a number of significant uncertainties, including when the ANPD’s director and members will be appointed and the timing and content of implementation regulations, which have yet to be issued. However, with the MPDFT filing the first public lawsuit less than one week after the LGPD took effect, it is critical that companies promptly assess their Brazilian operations and take the necessary steps to ensure LGPD compliance. We are monitoring the situation closely and will announce LGPD-related changes on a rolling basis, so check back here for updates.

    Authors

    Michael Silva

    Partner

    Miami

    More insights

  • HRSA Issues Proposed Rule Requiring Community Health Center Grant Recipients to Provide Certain Drugs to Low-Income Patients at 340B Prices

    ARTICLE / CLIENT ALERT

    HRSA Issues Proposed Rule Requiring Community Health Center Grant Recipients to Provide Certain Drugs to Low-Income Patients at 340B Prices

    September 28, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On September 24, 2020, the Health Resources and Services Administration (HRSA) released a proposed rule that, if finalized, would require 340B-participating recipients of federal grants under Section 330(e) of the Public Health Service Act (known as community health centers (CHCs)) to provide insulin and injectable epinephrine to low-income patients at 340B acquisition prices. HRSA will accept public comments on the proposed rule until October 28, 2020.

    In depth

    The proposed rule follows President Trump’s “Executive Order on Access to Affordable Life-saving Medications” and would add a requirement to future CHC funding awards under Section 330(e). The new condition of funding would require that the grantee “establish[] practices [to] provide insulin and injectable epinephrine at or below the discounted price paid by the health center grantee or sub-grantee under the 340B Drug Pricing Program (plus a minimal administration fee) to individuals with low incomes, as determined by the Secretary, who have a high cost sharing requirement for either insulin or injectable epinephrine; have a high unmet deductible; or have no health insurance.”

    The proposed rule defines certain terms, including:

    • Individuals with low incomes: individuals and families with annual incomes no greater than 350% of the Federal Poverty Guidelines
    • High cost sharing requirement: a cost sharing requirement that exceeds 20% of the amount the health center charges its patients for the drug
    • High unmet deductible: the amount a patient owes toward her high deductible at any time during a plan year in which the outstanding deductible portion exceeds 20% of the total deductible.

    Analysis and Takeaways

    HRSA’s proposed rule would amend 42 CFR 51c, a section of the federal regulations governing CHC grants, rather than regulations governing the 340B Program at 42 CFR 10. This approach should provide some comfort to 340B Program stakeholders that the requirements of the Executive Order will not be expanded to other 340B covered entity types. However, the limited scope will result in additional administrative burdens on 330(e) grantees and their sub-grantees, as well as reduced grant “program income” to support the programs under their grants. Notably, 330(e) grantees are already required to use any revenue generated from their 340B Program participation to support programs and patients served under their grants.

    Based on the comment period and standard rulemaking timeframes, it is unlikely that the proposed rule will be finalized before the beginning of the next presidential term, which begins on January 20, 2021.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Cathy Ren

    Partner

    Los Angeles

    More insights

  • Important U.S. Tax Considerations in Unwinding a C Corporate Structure

    Important U.S. Tax Considerations in Unwinding a C Corporate Structure

    ARTICLE

    Important U.S. Tax Considerations in Unwinding a C Corporate Structure

    September 28, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • FDA Issues Intended Use Proposed Rule, Repealing and Replacing January 2017 Final Rule

    FDA Issues Intended Use Proposed Rule, Repealing and Replacing January 2017 Final Rule

    ARTICLE / CLIENT ALERT

    FDA Issues Intended Use Proposed Rule, Repealing and Replacing January 2017 Final Rule

    September 25, 2020

    Read time: 9 min

    Key takeaways
    Overview

    On September 23, 2020, the US Food and Drug Administration (FDA) published its Regulations Regarding “Intended Uses” Proposed Rule to amend its “intended use” regulations at 21 C.F.R. §§ 201.128 and 801.4 and with the intent to clarify that how healthcare providers (HCPs) prescribe or use a product cannot be the sole basis for determining intended use. Comments on the Proposed Rule must be submitted to FDA by October 23, 2020.

    In depth

    On September 23, 2020, the US Food and Drug Administration (FDA) published its Regulations Regarding “Intended Uses” proposed rule (Proposed Rule) to amend its “intended use” regulations at 21 C.F.R. §§ 201.128 and 801.4. The Proposed Rule would amend FDA’s regulations regarding the types of evidence relevant to determining whether a product is intended for use as a drug or device under the Federal Food, Drug, and Cosmetic Act or Public Health Service Act and FDA’s implementing regulations for intended use. With the Proposed Rule, FDA intends to clarify that how healthcare providers (HCPs) prescribe or use a product cannot be the sole basis for determining intended use, a nod to the fact FDA does not regulate the practice of medicine and the fact that HCPs frequently use medical products off-label, or outside the manufacturer’s cleared or approved intended use, in their professional judgment.

    Specifically, FDA proposes to:

    • Delete the last sentence of 21 C.F.R. § 201.128 and 801.4, respectively, and to insert a new clause stating “provided, however, that a firm would not be regarded as intending an unapproved new use for an [approved or cleared medical product] based solely on that firm’s knowledge that such [product] was being prescribed or used by health care providers for such use.”
    • Amend the text of these regulations to provide additional clarification regarding the types of evidence that the agency may deem relevant in determining a product’s intended use.
    • Insert in these regulations a reference to 21 C.F.R. § 1100.5, which describes when a product made or derived from tobacco that is intended for human consumption will be regulated as a drug, device or combination product to clarify the interplay between the drug/biologic and device intended use regulations, respectively, and FDA’s tobacco product regulations.
    21 C.F.R. § 201.128 21 C.F.R. § 801.4
    The words intended uses or words of similar import in 201.5, 201.115, 201.117, 201.119, 201.120, and 201.122, and 1100.5 of this chapter refer to the objective intent of the persons legally responsible for the labeling of drugs an article (or their representatives). The intent is determinedmay be shown by such persons’ expressions, the design or composition of the article, or may be shownby the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. Objective intentIt may be shown by thecircumstances thatin which the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised; provided, however, that a firm would not be regarded as intending an unapproved new use for an approved drug based solely on that firm’s knowledge that such drug was being prescribed or used by health care providers for such use. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the drugarticle, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses. But if a manufacturer knows, or has knowledge of facts that would give him notice, that a drug introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a drug which accords with such other uses to which the article is to be put. The words intended uses or words of similar import in 801.5, 801.119, and801.122, and 1100.5 of this chapter refer to the objective intent of the persons legally responsible for the labeling of devices an article (or their representatives). The intent is determined may be shown by such persons’ expressions, the design or composition of the article, or may be shown by the circumstances surrounding the distribution of the article. Objective intentIt may be shown by thecircumstances thatin which the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised; provided, however, that a firm would not be regarded as intending an unapproved new use for an approved or cleared device based solely on that firm’s knowledge that such device was being prescribed or used by health care providers for such use. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the devicearticle, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses. But if a manufacturer knows, or has knowledge of facts that would give him notice that a device introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a device which accords with such other uses to which the article is to be put.

    In the preamble to the Proposed Rule, FDA included other examples of evidence that it does not consider to be determinative of intended use, standing alone:

    • Limited instances where a firm disseminates safety information about unapproved uses to HCPs to minimize risks to patients
    • A manufacturer’s official social media account “following” other social media accounts that relate to uncleared or unapproved indications, provided the manufacturer does not comment or endorse any specific posts on the other social media accounts
    • Internal sales figures related to uncleared or unapproved uses
    • Corporate filings or submissions to the Securities and Exchange Commission that include required disclosures of development activities or potential actual sales for uncleared or unapproved uses
    • Summaries of aggregated clinical trial results provided to trial subjects to acknowledge their contributions, provided summaries are factual, balanced and complete presentations of trial results and do not make any conclusions about the safety or effectiveness of the uncleared or unapproved product or use and contain conspicuous and prominent statements that the product or use has not been cleared, approved or licensed by FDA.

    However, the agency reaffirmed its longstanding position that the intended use of a product can be evaluated based on “any relevant source of evidence,” including direct and circumstantial evidence. This may include a product’s labeling, express or implied promotional claims, advertising and any other relevant evidence. This may include consumer intent if it is relevant to demonstrating the seller’s intent, training programs, financial arrangements, and other circumstances surrounding the manufacture, distribution, promotion or sale of a product. FDA provided a list of potentially relevant evidence in the preamble to the Proposed Rule, including:

    • Express claims or representations
    • Implied claims (including suggestive names and representations that the product contains a particular ingredient to imply a physiological effect)
    • Product characteristics and design (including known physiological effects, known uses, and design or technical features)
    • Circumstances of sale or distribution (circumstances and context surrounding the sale, and to whom and for whom the products are offered).

    Rulemaking Background

    The Proposed Rule, if finalized, would have the effect of repealing and replacing portions of FDA’s January 9, 2017 final rule (2017 Final Rule), “Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding ‘Intended Uses’” (82 Fed. Reg. 2193, 2196 (Jan. 9, 2017), first proposed in 2015 (2015 Proposed Rule).

    Whereas, in the 2015 Proposed Rule, FDA proposed to strike the last sentence of 21 C.F.R. §§ 201.128 and 801.4, respectively, in the 2017 Final Rule, FDA amended the last sentence of these respective regulations to clarify that the agency, absent “extraordinary circumstances,” would not consider a manufacturer as intending an uncleared or unapproved new use for a device based solely on the manufacturer’s knowledge that the product was being used or prescribed by doctors for such use. Rather, under the 2017 Final Rule, a manufacturer was not obligated to provide adequate labeling for that uncleared or unapproved use unless the totality of the evidence showed the manufacturer intended for its device to be used for that use.

    However, the agency received an industry petition to stay and for reconsideration, which raised concerns that the amended language did not make clear that a manufacturer’s mere knowledge of an unapproved new use would not automatically trigger requirements for new labeling (that would, in turn, render distribution of that approved product unlawful without a new or supplemental marketing authorization). As a result, the agency delayed the 2017 Final Rule’s effective date and reopened the comment period to allow further consideration of the substantive issues raised in additional comments. As a result, with respect to the “intended use” definitions, the Proposed Rule essentially reflects a reversion to the 2015 Proposed Rule.

    Comments on the Proposed Rule may be submitted to Docket FDA-2015-N-2002 by October 23, 2020.

    Authors

    Michael W. Ryan

    Partner

    Washington, DC

    More insights

  • DOL’s PRO Good Guidance Rule:  Rule Clarifies Which Materials Are Binding, Which Are Not

    DOL’s PRO Good Guidance Rule: Rule Clarifies Which Materials Are Binding, Which Are Not

    ARTICLE

    DOL’s PRO Good Guidance Rule: Rule Clarifies Which Materials Are Binding, Which Are Not

    September 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • SEC Increases Rule 14a-8 Thresholds for Shareholders to Submit Proposals in Company Proxy Materials

    SEC Increases Rule 14a-8 Thresholds for Shareholders to Submit Proposals in Company Proxy Materials

    ARTICLE / CLIENT ALERT

    SEC Increases Rule 14a-8 Thresholds for Shareholders to Submit Proposals in Company Proxy Materials

    September 25, 2020

    Read time: 4 min

    Key takeaways
    Overview

    The U.S. Securities and Exchange Commission (“Commission”) has adopted amendments to the proxy rules to increase the threshold requirements for shareholders to access a company’s proxy materials. These new rules will make it more difficult for certain shareholders seeking to submit shareholder proposals for inclusion at a company’s special or annual meeting of shareholders.

    Previously, Rule 14a-8 of the Securities Exchange Act of 1934 provided that for a shareholder to submit a proposal for inclusion in a company’s proxy materials, the shareholder must have continuously held at least $2,000 in market value, or 1%, of the company’s securities entitled to vote on the proposal for at least one year by the date the proposal is submitted. Under the new rules, such test is replaced with the following three alternative thresholds that will require a shareholder to demonstrate continuous ownership of at least:

    1. $2,000 of the company’s securities for at least three years;
    2. $15,000 of the company’s securities for at least two years; or
    3. $25,000 of the company’s securities for at least one year.

    The Commission is eliminating a percentage-based component for shareholder ownership. Given that market value may change due to market fluctuations, the Commission advises that shareholders should determine the market value of their securities by multiplying the number of securities the shareholder continuously held for the relevant period by the highest selling price during the 60 calendar days before the shareholder submitted the proposal.

    The new rules have also increased the amount of voter support necessary for any shareholder to resubmit the same or a similar proposal in a shareholder meeting within five years of the proposal’s submission. Under the new rules, a company may exclude a proposal from its proxy materials for any meeting held within three years of the last time it was included if the proposal received:

    1. Less than 5% of the vote if proposed once within the preceding five years;
    2. Less than 15% of the vote on its last submission to shareholders if proposed twice previously within the preceding five years; or
    3. Less than 25% of the vote on its last submission to shareholders if proposed three times or more previously within the preceding five years.

    Previously, the thresholds were 3%, 6% and 10%, respectively.

    The SEC’s release also, among other things, included the following changes to Rule 14a-8:

    1. Requires the shareholder to include a written representation that the shareholder will be available (and to include dates and times of availability) to meet with the company in person or via teleconference no less than 10 calendar days, nor more than 30 calendar days, after submission of the shareholder proposal;
    2. Requires a shareholder who uses a representative (including any investment adviser who submits on the shareholder’s behalf) to provide signed and dated documentation of the shareholder’s identity, role and interest in the proposal; and
    3. Applies the one-proposal rule to “each person” rather than “each shareholder” so a single person cannot, for example, submit multiple proposals on behalf of other shareholders.

    These amendments will be effective 60 days after publication in the Federal Register. The final amendments will apply to any proposal submitted for any annual or special meeting held on or after  Jan. 1, 2022. The final rules will also provide for a transition period with respect to the ownership thresholds that will allow reliance on the prior $2,000 for one-year ownership threshold for proposals submitted for a shareholder meeting held prior to Jan. 1, 2023.

    The SEC’s press release and fact sheet on the changes can be found here and the adopting release can be found here.

    Authored by Eleazer Klein, Daniel A. Goldstein and David M. Rothenberg.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    Daniel A. Goldstein

    Counsel

    New York – 919 Third Avenue

    More insights

  • District of Columbia Wills

    ARTICLE

    District of Columbia Wills

    September 2020

    Read time: 2 min

    Key takeaways
    Overview

    Caitlin Orr and Carl William Rush provide a guide on this topic in Practical Law, a resource by Thomson Reuters.

    Access the guide by clicking here.

    In depth
    Authors

    Carl William Rush

    Partner

    Washington, DC

    More insights

  • New Jersey Reconsiders Financial Transaction Tax

    New Jersey Reconsiders Financial Transaction Tax

    ARTICLE

    New Jersey Reconsiders Financial Transaction Tax

    September 24, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Stephen P. Kranz

    Partner

    Washington, DC

    More insights

  • The Confused State of Virtual Currency Taxation in 2020

    The Confused State of Virtual Currency Taxation in 2020

    ARTICLE

    The Confused State of Virtual Currency Taxation in 2020

    October 2020

    Read time: 2 min

    Key takeaways
    Overview

    Partner, Andrea Kramer discusses several key tax principles and how they relate to virtual currency taxation in Taxes – The Tax Magazine.

    In depth
    Authors
    More insights

  • DOL Creates Path for 401(k) Plans to Offer Private Equity Investment Options

    DOL Creates Path for 401(k) Plans to Offer Private Equity Investment Options

    ARTICLE

    DOL Creates Path for 401(k) Plans to Offer Private Equity Investment Options

    September 23, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Todd A. Solomon

    Partner

    Chicago

    Brian J. Tiemann

    Partner

    Chicago

    More insights